Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16475177 | 0.81 | MAPT (0.33) | F2RL1 | |
| SCHEMBL16475117 | 0.77 | ALDH1A1 (0.35) | F2RL1 | |
| SCHEMBL3989639 | 0.77 | PIK3CB (0.30) | — | |
| SCHEMBL31083207 | 0.77 | PIK3CB (0.30) | — | |
| SCHEMBL16475120 | 0.76 | KDM4E (0.33) | F2RL1 | |
| SCHEMBL2121254 | 0.67 | KDM4E (0.33) | — | |
| SCHEMBL26114333 | 0.67 | CYP19A1 (0.33) | RAB9A | |
| SCHEMBL12513707 | 0.66 | PIK3CB (0.30) | — | |
| SCHEMBL23906401 | 0.66 | ADORA2A (0.37) | F2RL1RAB9A | |
| SCHEMBL2128728 | 0.65 | F2RL1 (0.31) | F2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903991-B1 | ANTI-FIBROTIC PYRIDINONES | INTERMUNE INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675593-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359379-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064692-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | F2RL1 485/4885RAB9A 2353/4885 |
| US-20140107110-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | F2RL1 485/4885RAB9A 2353/4885 |
| US-20160263090-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | F2RL1 485/4885RAB9A 2353/4885 |
| US-20170121345-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | F2RL1 485/4885RAB9A 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.